CVCT 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012

Mise en ligne : 01 décembre 2012
  • niveau 1 niveau 2 niveau 3
  • audio 1 audio 2 audio 3
  • document 1 document 2 document 3
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Industry perspective (Holger WOEHRLE)

Vidéos

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Industry perspective (Holger WOEHRLE)
Conférence
00:06:29
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Industry perspectiv…
Woehrle
Holger

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Non randomized and/or non-blinded trials (Stuart POCOCK)
Conférence
00:23:13
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Non randomized and/…
Pocock
Stuart J.

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Joerg KOGLIN)
Conférence
00:07:08
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Joer…
Koeck
Jean-Louis

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Krishna PRASAD)
Conférence
00:09:32
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is hear…
Prasad
Krishna

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Faiez ZANNAD)
Conférence
00:52:36
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is hear…

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Efthymios DELIARGYRIS)
Conférence
00:13:06
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is hear…
Deliargyris
Efthymios

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Different doses, different indications? (Freek VERHEUGT)
Conférence
00:26:04
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Different doses, differe…
Verheugt
Freek

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : How to secure the optimal dose(s) for phase III? (Michael GIBSON)
Conférence
01:09:44
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : How to secure the optima…

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : Well Established Methods for Imaging Approaches, IVUS and IMT (Wolfgang KOENIG)
Conférence
00:15:02
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : Well Established Methods…
Koenig
Wolfgang

MODIGLIANI Workshop 2 - Friday November 30, 2012 : ATHEROSCLEROSIS IMAGING IN CLINICAL TRIALS Facilitating the discovery of effective therapies Chairpersons: Jagat NARULA, New York, USA - Ahmed

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Options of and alternatives to the “control group” in device trials (William T. ABRAHAM)
Conférence
00:16:44
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Options of and alte…
Abraham
William T.

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : How to secure the optimal dose(s) for phase III? (Nancy GELLER)
Conférence
00:12:25
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : How to secure the optima…

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story post-EVEREST  (Michael FELKER)
Conférence
00:12:12
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story …

MODIGLIANI Debate Session 5 - Saturday December 1st, 2012 NOVEL DIURETIC STRATEGIES IN HEART FAILURE Chairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITA Webcast: Patrick

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story post-EVEREST  (William T. ABRAHAM)
Conférence
00:12:13
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story …
Abraham
William T.

MODIGLIANI Debate Session 5 - Saturday December 1st, 2012 NOVEL DIURETIC STRATEGIES IN HEART FAILURE Chairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITA Webcast: Patrick

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Ultrafiltration for acute cardiorenal syndrome in heart failure (Gian Paolo ROSSI)
Conférence
00:51:34
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Ultrafiltration fo…

MODIGLIANI Debate Session 5 - Saturday December 1st, 2012 NOVEL DIURETIC STRATEGIES IN HEART FAILURE Chairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITA Webcast: Patrick

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Insights from DOSE and gaps in evidence with diuretic therapy (Alice MASCETTE)
Conférence
00:31:41
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Insights from DOSE…

MODIGLIANI Debate Session 5 - Saturday December 1st, 2012 NOVEL DIURETIC STRATEGIES IN HEART FAILURE Chairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITA Webcast: Patrick

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials? (Eric STROES)
Conférence
00:14:25
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Will we be able to answe…
Stroes
Eric

MODIGLIANI Workshop 5 - Saturday December 1st, 2012 THE ATHEROSCLEROSIS TRIALISTS FORUM Chairpersons: Wolfgang KOENIG, Ulm, GER - Anthony WIERZBICKI, London, GBR Webcast: Tabassome SIMON, Paris, FRA

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 4 : What endpoint for securing approval and reimbursement (Andrew FARB - Ileana PIÑA)
Conférence
00:22:56
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 4 : What endpoint for …
Pina
Ileana
Farb
Andrew

MODIGLIANI Debate Session 4 - Saturday December 1st, 2012: HEART FAILURE REMOTE MONITORING TRIALS Chairpersons: Stefan ANKER, Berlin, GER - Ileana PIÑA, New York, USA Webcast: Daniela DOBRE, Nancy,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 4 : Treatment optimization (William T. ABRAHAM)
Conférence
00:28:04
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 4 : Treatment optimiza…
Abraham
William T.

MODIGLIANI Debate Session 4 - Saturday December 1st, 2012: HEART FAILURE REMOTE MONITORING TRIALS Chairpersons: Stefan ANKER, Berlin, GER - Ileana PIÑA, New York, USA Webcast: Daniela DOBRE, Nancy,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Will we be able to answer the question of HDL as a therapeutic target after the CETP inhibitor trials? (Robert ROSENSON)
Conférence
00:58:16
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Will we be able to answe…
Rosenson
Robert

MODIGLIANI Workshop 5 - Saturday December 1st, 2012 THE ATHEROSCLEROSIS TRIALISTS FORUM Chairpersons: Wolfgang KOENIG, Ulm, GER - Anthony WIERZBICKI, London, GBR Webcast: Tabassome SIMON, Paris, FRA

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Identifying new targets: Monoclonal Antibody Inhibitor of PCSK9 (Wolfgang KOENIG)
Conférence
00:16:49
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Identifying new targets:…
Koenig
Wolfgang

MODIGLIANI Workshop 5 - Saturday December 1st, 2012 THE ATHEROSCLEROSIS TRIALISTS FORUM Chairpersons: Wolfgang KOENIG, Ulm, GER - Anthony WIERZBICKI, London, GBR Webcast: Tabassome SIMON, Paris, FRA

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : Regulatory viewpoint  (Yuki ANDO)
Conférence
00:13:53
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : Regulatory viewpoin…
Ando
Yuki

MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012: HEART FAILURE TRIALISTS WORKSHOP LEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALS Chairpersons: Alexandre

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : The value of repeat events in post discharge hospitalized HF trials (Stuart POCOCK)
Conférence
00:34:34
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : The value of repeat…
Pocock
Stuart J.

MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012: HEART FAILURE TRIALISTS WORKSHOP LEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALS Chairpersons: Alexandre

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : RELAX-HF (Michael FELKER)
Conférence
00:24:07
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : RELAX-HF (Michael F…

MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012: HEART FAILURE TRIALISTS WORKSHOP LEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALS Chairpersons: Alexandre

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : ASTRONAUT (Aldo MAGGIONI)
Conférence
00:16:18
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : ASTRONAUT (Aldo MAG…

MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012: HEART FAILURE TRIALISTS WORKSHOP LEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALS Chairpersons: Alexandre

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : Execution issues (Mihai GHEORGHIADE)
Conférence
00:21:53
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : Execution issues (M…

MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012: HEART FAILURE TRIALISTS WORKSHOP LEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALS Chairpersons: Alexandre

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : PRONTO (Frank PEACOCK)
Conférence
01:33:59
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : PRONTO (Frank PEACO…

MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012: HEART FAILURE TRIALISTS WORKSHOP LEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALS Chairpersons: Alexandre

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : Endpoint related issues (Alexandre MEBAZAA)
Conférence
00:25:32
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : Endpoint related is…

MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012: HEART FAILURE TRIALISTS WORKSHOP LEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALS Chairpersons: Alexandre

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Identifying new targets: The value of omics and mendelian randomization studies (Daniel SWERDLOW)
Conférence
01:06:54
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Identifying new targets:…
Swerdlow
Daniel

MODIGLIANI Workshop 5 - Saturday December 1st, 2012 THE ATHEROSCLEROSIS TRIALISTS FORUM Chairpersons: Wolfgang KOENIG, Ulm, GER - Anthony WIERZBICKI, London, GBR Webcast: Tabassome SIMON, Paris, FRA

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 :How to secure the optimal dose(s) for phase III? How to secure the optimal dose(s) for phase III?
Conférence
00:23:45
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 :How to secure the optimal…

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 :Regulatory viewpoint (Pieter DE GRAEF)
Conférence
00:36:29
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 :Regulatory viewpoint (Pie…

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : How much one could deviate from “randomized - controlled” trials? Questions
Conférence
00:19:04
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : How much one could …

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Post approval and registry studies (Roxana MEHRAN)
Conférence
00:12:25
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Post approval and r…
Mehran
Roxana

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Industry perspective (Rob KIEVAL)
Conférence
00:08:52
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Industry perspectiv…
Kieval
Rob

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Comparative effectiveness studies (Rita REDBERG)
Conférence
00:33:42
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Comparative effecti…
Redberg
Rita F.

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Comparative effectiveness studies (Kenneth STEIN)
Conférence
00:21:52
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Comparative effecti…
Stein
Kenneth

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Post approval and registry studies (Ileana PIÑA)
Conférence
00:10:07
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Post approval and r…
Pina
Ileana

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Approvability issues: Pathway to a more global device approval process (Ileana PIÑA)
Conférence
01:17:56
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 1 : Approvability issue…
Pina
Ileana

MODIGLIANI Lunch Debate Session 1 - Friday November 30, 2012 THE DEVICE THERAPY TRIALISTS WORKSHOP Chairpersons: Gaetano DE FERRARI, Pavia, ITA - Ileana PIÑA, New York, USA Webcast: Tariq AHMAD,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : PET-CT imaging in clinical trials (James RUDD)
Conférence
00:33:59
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 2 : PET-CT imaging in clinic…
Rudd
James

MODIGLIANI Workshop 2 - Friday November 30, 2012 : ATHEROSCLEROSIS IMAGING IN CLINICAL TRIALS Facilitating the discovery of effective therapies Chairpersons: Jagat NARULA, New York, USA - Ahmed

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Yasser KHDER)
Conférence
00:06:43
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Yass…
Khder
Yasser

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Dosing Issues, Questions
Conférence
00:15:21
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Dosing Issues, Questions

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Different doses, different indications? (Maarten SIMOONS)
Conférence
00:17:48
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Different doses, differe…
Simoons
Maarten L.

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is heart failure a viable new potential indication for anti-thrombosis therapy (Lloyd HASKEL)
Conférence
00:12:36
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : New indications: Is hear…
Haskel
Lloyd

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Regulatory viewpoint (Kaori SHINAGAWA)
Conférence
00:08:24
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Regulatory viewpoint (Ka…
Shinagawa
Kaori

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Christophe GAUDIN)
Conférence
00:08:07
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Industry viewpoint (Chri…

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Regulatory viewpoint (Angeles ALONSO)
Conférence
00:07:13
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 1 : Regulatory viewpoint (An…

MODIGLIANI Workshop 1 - Friday November 30, 2012 : THE THROMBOSIS TRIALISTS WORKSHOP DOSE AND TARGET PATIENT POPULATIONS ISSUES Chairpersons: Peter CLEMMENSEN, Copenhagen, DEN - George-Andrei DAN,

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries.
Conférence
00:29:24
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and…
Maggioni
Aldo

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries • NICE Speaker: Suzanna HARDMAN, London, GBR • German CHF registry:

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries.
Conférence
00:13:56
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and…
Tschoepe
Carsten

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries. • NICE Speaker: Suzanna HARDMAN, London, GBR • German CHF registry:

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : conclusion
Conférence
00:07:27
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : conclusion
Bakris
George L.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : conclusion George BAKRIS, Chicago, USA - Sverre E. KJELDSEN, Oslo, NOR Abstract : conclusion L’auteur n’a pas transmis de conflit

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement
Conférence
00:04:13
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in a…
Stein
Kenneth

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement
Conférence
00:19:42
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in a…
Farb
Andrew

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement
Conférence
00:08:37
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in a…
Bakris
George L.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Autonomic modulation therapy for heart failure: Preclinical data and ongoing trials
Conférence
00:11:49
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Autonomic modulation therapy for hear…

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Autonomic modulation therapy for heart failure: Preclinical data and ongoing trials Speaker: Faiez ZANNAD, Nancy, FRA Discussant:

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Barostim: Experience so far and future developments
Conférence
00:07:21
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Barostim: Experience so far and futur…
Yared
Nadim

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Barostim: Experience so far and future developments Speaker: Hermann HALLER, Hannover, GER Discussant: Nadim YARED, CVRx, USA

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure?
Conférence
00:14:04
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can re…
Azizi
Michel

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure? Speaker: Felix MAHFOUD, Homburg, GER Discussant

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure?
Conférence
00:14:44
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can re…
Mahfoud
Felix

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure? Speaker: Felix MAHFOUD, Homburg, GER Discussant

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable.
Should there be a position statement establishing rules for biomarker studies?
Conférence
00:04:01
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There …
Fiuzat
Mona

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable.
Should there be a position statement establishing rules for biomarker studies?
Conférence
00:03:23
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There …
Redberg
Rita F.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate led by Journal Editors: There are too many studies and the quality is variable. Should there be a position statement

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures
Conférence
00:17:29
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there o…

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Biomarker guided-therapy: Are there other endpoints besides mortality that matter? Selecting the best outcome measures Speaker:

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates).
Conférence
00:10:00
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for…
Blankenberg
Stefan

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate : Best statistical methods for evaluating the merits of a novel marker (debates). Speaker: Stefan BLANKENBERG, Hamburg, GER

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker
Conférence
00:07:58
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluati…

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker Speaker: Stefan BLANKENBERG, Hamburg, GER Discussant: Nancy

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker
Conférence
00:14:50
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluati…
Blankenberg
Stefan

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Best statistical methods for evaluating the merits of a novel marker Speaker: Stefan BLANKENBERG, Hamburg, GER Discussant: Nancy

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?
Conférence
00:15:36
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic mark…
Snider
James

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied? Speaker: Jim JANUZZI, Boston, USA Discussant: James SNIDER, Critical

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?
Conférence
00:16:36
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic mark…
Januzzi
Jim

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied? Speaker: Jim JANUZZI, Boston, USA Discussant: James SNIDER, Critical

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints
Conférence
00:13:18
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints
Redberg
Rita F.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints Speaker: Joseph LOSCALZO, Boston, USA, Circulation Discussant: Rita REDBERG, San Francisco, USA, Arch

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints
Conférence
00:04:37
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints
Jarcho
John

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Journal editor’s viewpoints Speaker: John JARCHO, Boston, USA, NEJM Discussant: Rita REDBERG, San Francisco, USA, Arch Intern Med

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : The role of biomarkers
Conférence
00:36:51
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : The role of biomarkers
Blankenberg
Stefan

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : The role of biomarkers Speaker: Stefan BLANKENBERG, Hamburg, GER Abstract : The role of biomarkers L’auteur n’a pas transmis de

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate Omics research and system biology. Keys for future personalized medicine
How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.
Conférence
00:41:45
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate Omics research and system biol…

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : debate Omics research and system biology. Keys for future personalized medicine How future trials may help optimizing benefit-to

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Keys for future personalized medicine
How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.
Conférence
00:13:32
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Ke…

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Keys for future personalized medicine How future trials may help optimizing benefit-to-risk

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Keys for future personalized medicine
How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations.
Conférence
00:17:43
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Omics research and system biology. Ke…

How future trials may help optimizing benefit-to-risk ratio. The role of specialist scientific organizations. ISCP: Speaker: Felipe MARTINEZ, Cordoba, ARG CVCT: Speaker: Faiez ZANNAD, Nancy, FRA ESC

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Is it always safe to believe in class effect: Spironolactone vs. eplerenone differences and clinical relevance?
Conférence
00:32:48
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Is it always safe to believe in class…
Pitt
Bertram

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Is it always safe to believe in class effect: Spironolactone vs. eplerenone differences and clinical relevance? Speaker: Bertram

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Compound vs. class effect. Drug class recommendations in guidelinesCanadian, Australian CHF guideline and 2010 NICE guideline.
Conférence
00:12:31
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Compound vs. class effect. Drug class…
Ezekowitz
Justin

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Compound vs. class effect. Drug class recommendations in guidelinesCanadian, Australian CHF guideline and 2010 NICE guideline.

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Expected implications on heart failure epidemiology.
Conférence
00:37:34
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Expected implications on heart failur…
Ezekowitz
Justin

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Expected implications on heart failure epidemiology. Speaker: Justin EZEKOWITZ, Edmonton, CAN Abstract : Expected implications on

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Impact of major clinical trials on ESC Chronic Heart Failure 2012 guidelines. Game changer trials: EMPHASIS-HF, SHIFT, Devices…
Conférence
00:11:34
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Impact of major clinical trials on ES…
Zannad
Faiez

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Impact of major clinical trials on ESC Chronic Heart Failure 2012 guidelines. Game changer trials: EMPHASIS-HF, SHIFT, Devices…

Cardiovascular Clinical Trialists (CVCT) Forum – Interpretation and approvability issues.
Conférence
00:14:10
Cardiovascular Clinical Trialists (CVCT) Forum – Interpretation and approvability issues.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Interpretation and approvability issues. Industry viewpoint: Paul AUDHYA, Reata, USA Regulatory viewpoint: Pieter DE GRAEF, EMEA, NED Abstract

Cardiovascular Clinical Trialists (CVCT) Forum – RAAS inhibitors and Mineralocorticoid receptor antagonists (FOSIDIAL, ALCHEMIST)
Conférence
00:22:31
Cardiovascular Clinical Trialists (CVCT) Forum – RAAS inhibitors and Mineralocorticoid receptor ant…
Rossignol
Patrick

Title : Cardiovascular Clinical Trialists (CVCT) Forum – RAAS inhibitors and Mineralocorticoid receptor antagonists (FOSIDIAL, ALCHEMIST) Speaker: Patrick ROSSIGNOL, Nancy, FRA Abstract : RAAS

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients (debates).
Conférence
00:09:24
Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in h…
Massy
Ziad

Title : Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients (debates). Speakers: Chris MIX, Amgen, USA - David WHEELER, London, GBR

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients
Conférence
00:10:17
Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in h…

Title : Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients Speakers: Chris MIX, Amgen, USA - David WHEELER, London, GBR Discussant:

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients
Conférence
00:10:30
Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in h…
Massy
Ziad

Title : Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients Speakers: Chris MIX, Amgen, USA - David WHEELER, London, GBR Discussant:

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients.
Conférence
00:20:05
Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in h…

Title: Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients. Speakers: Chris MIX, Amgen, USA - David WHEELER, London, GBR Discussant:

Cardiovascular Clinical Trialists (CVCT) Forum – Lipid lowering agents. Now, we have an option! (SHARP, 4D, AURORA)
Conférence
00:26:39
Cardiovascular Clinical Trialists (CVCT) Forum – Lipid lowering agents. Now, we have an option! (SH…
Baigent
Colin

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Lipid lowering agents. Now, we have an option! (SHARP, 4D, AURORA) Speaker: Colin BAIGENT, Oxford, GBR Abstract : Lipid lowering agents. Now,

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Save life and save cost with ivabradine.
Conférence
00:46:30
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Save life and save cost with ivabradi…
Cowie
Martin

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Save life and save cost with ivabradine. Speaker: Martin COWIE, London, GBR Abstract :  Clinical evidence suggests that an

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure management.
Conférence
00:57:34
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure ma…

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : SHIfTing evidence in heart failure management. Speaker: Jeffrey BORER, New York, USA Abstract : SHIFT (Systolic Heart failure

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : on top of or vs. Metformin? The issue of background therapy and comparator
Conférence
00:19:18
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : o…
Marre
Michel

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : on top of or vs. Metformin? The issue of background therapy and comparator Speaker: Michel

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance (debates).
Conférence
00:10:39
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both…
Pocock
Stuart J.

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : <br>Non-inferiority, superiority, or both? Operationalizing the FDA guidance (debates). Speaker: Marc PFEFFER,

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance
Conférence
00:12:25
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both…
Dunder
Kristina

Title :Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance Speaker: Marc PFEFFER, Boston, USA Discussant: Stuart

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance
Conférence
00:15:46
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both…
Pocock
Stuart J.

Title: Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance Speaker: Marc PFEFFER, Boston, USA Discussant: Stuart

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy (debates).
Conférence
00:11:49
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy (de…
Marre
Michel

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : <br>Study drug and background therapy (debates). Speaker: Denise BONDS, NHLBI, USA Speaker: Michel MARRE, Paris, FRA

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : What else than glucose control? Lipids, BP, Weight, Kidney
Conférence
00:15:00
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : What else than glucose control? Lipid…
Bonds
Denise

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : What else than glucose control? Lipids, BP, Weight, Kidney Speaker: Denise BONDS, NHLBI, USA Abstract : What else than glucose

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : Insulin in type 2 diabetes: bad guy or good guy?
Conférence
00:17:12
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : I…
Marre
Michel

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Study drug and background therapy : Insulin in type 2 diabetes: bad guy or good guy? Speaker: Michel MARRE, Paris, FRA Abstract :

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful? (debates)
Conférence
00:44:47
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-st…

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : <br>Target populations: How do we risk-stratify? Are additional biomarkers helpful? (debates) Speaker: Wolfgang

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful?
Conférence
00:09:45
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-st…

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful? Speaker: Wolfgang KOENIG, Ulm, GER Discussant:

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful?
Conférence
00:13:23
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-st…
Koenig
Wolfgang

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Target populations: How do we risk-stratify? Are additional biomarkers helpful? Speaker: Wolfgang KOENIG, Ulm, GER Discussant:

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries (debates).
Conférence
00:19:16
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epi…
Sobhy
Mohamed

Title : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries (debates). Prem PAIS, Bangalore, IND Speaker: Mohamed SOBHY, Alexandria, EGY Abstract :

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries
Conférence
00:11:49
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epi…
Sobhy
Mohamed

Title : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries Speaker: Mohamed SOBHY, Alexandria, EGY Abstract : Diabetes is one of the major public health

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries
Conférence
00:14:53
Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Globalization of Diabetes trials: Epi…
Pais
Prem

Title : Globalization of Diabetes trials: Epidemiology of diabetes in the Middle East and Asian countries Speaker: Prem PAIS, Bangalore, IND Abstract : India has a high prevalence of type 2 diabetes

Intervenants